Erasca Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
103
- Stock Symbol
-
ERAS
- Share Price
-
$15.65
- (As of Friday Closing)
Erasca General Information
Description
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
Contact Information
Website
www.erasca.comCorporate Office
- 3115 Merryfield Row
- Suite 300
- San Diego, CA 92121
- United States
Corporate Office
- 3115 Merryfield Row
- Suite 300
- San Diego, CA 92121
- United States
Erasca Stock Performance
As of 13-Nov-2026, Erasca’s stock price is $15.65. Its current market cap is $5.5B with 351M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $15.65 | $15.78 | $2.50 - $24.28 | $5.5B | 351M | 4.82M | -$0.97 |
Erasca Financials Summary
As of 30-Sep-2026, Erasca has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 4,903,487 | 815,301 | 443,672 | 81,905 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (324,930) | (138,046) | (177,938) | (138,022) |
| Net Income | (307,942) | (124,546) | (161,650) | (125,042) |
| Total Assets | 998,936 | 396,154 | 502,526 | 395,297 |
| Total Debt | 43,407 | 47,139 | 51,889 | 55,859 |
Erasca Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Erasca Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Erasca Comparisons
Industry
Financing
Details
Erasca Competitors (39)
One of Erasca’s 39 competitors is Arvinas, a Formerly VC-backed company based in New Haven, CT.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Arvinas | Formerly VC-backed | New Haven, CT | ||||
| Valerio Therapeutics | Formerly VC-backed | Paris, France | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Agenus | Formerly VC-backed | Lexington, MA |
Erasca Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Erasca Patents
Erasca Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026178303-A1 | Method of treatment of double wt melanoma | Pending | 21-Feb-2025 | ||
| WO-2026165003-A1 | Has and ctla-4 inhibitors combination therapy for the treatment of cancer | Pending | 28-Jan-2025 | ||
| WO-2026165003-A8 | Ras and ctla-4 inhibitors combination therapy for the treatment of cancer | Pending | 28-Jan-2025 | ||
| WO-2026151993-A1 | Method of treatment of drug-induced skin toxicity | Pending | 10-Jan-2025 | ||
| WO-2026107237-A1 | Ras and egfr inhibitors combination therapy | Pending | 15-Nov-2024 | A61K45/06 |
Erasca Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Erasca ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
39.79 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Erasca FAQs
-
When was Erasca founded?
Erasca was founded in 2018.
-
Where is Erasca headquartered?
Erasca is headquartered in San Diego, CA.
-
What is the size of Erasca?
Erasca has 103 total employees.
-
What industry is Erasca in?
Erasca’s primary industry is Drug Discovery.
-
Is Erasca a private or public company?
Erasca is a Public company.
-
What is Erasca’s stock symbol?
The ticker symbol for Erasca is ERAS.
-
What is the current stock price of Erasca?
As of 13-Nov-2026 the stock price of Erasca is $15.65.
-
What is the current market cap of Erasca?
The current market capitalization of Erasca is $5.5B.
-
Who are Erasca’s competitors?
Arvinas, Valerio Therapeutics, Adaptimmune Therapeutics, Immunocore Holdings, and Agenus are some of the 39 competitors of Erasca.
-
What is Erasca’s annual earnings per share (EPS)?
Erasca’s EPS for 12 months was -$0.97.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
